Skip to Content

Revcovi Approval History

FDA Approved: Yes (First approved October 5, 2018)
Brand name: Revcovi
Generic name: elapegademase-lvlr
Dosage form: Injection
Company: Leadiant Biosciences, Inc.
Treatment for: Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID)

Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).

Development History and FDA Approval Process for Revcovi

DateArticle
Oct  5, 2018Approval FDA Approves Revcovi (elapegademase-lvlr) for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide